Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy by Dündar, Bumin Nuri et al.
J Clin Res Ped Endo 2009;1(4):181-187
DOI: 10.4008/jcrpe.v1i4.56
ISSN: 1308-5727
Online ISSN: 1308-5735
© 2009 Journal of Turkish Pediatric Endocrinology and Diabetes Society
Pubbiz/Probiz Ltd. ﬁti.
181
Comparison of the Efficacy and Safety of
Insulin Glargine and Insulin Detemir with
NPH Insulin in Children and Adolescents with
Type 1 Diabetes Mellitus Receiving Intensive
Insulin Therapy
Bumin Nuri Dündar1, Nihal Dündar2, Erdal Eren3
1 Department of Pediatric Endocrinology, Süleyman Demirel University, Faculty of Medicine, Isparta
2 Department of Pediatrics, Süleyman Demirel University, Faculty of Medicine, Isparta
3 Department of Pediatric Endocrinology, Uluda¤ University, Faculty of Medicine, Bursa
ORIGINAL
ARTICLE
Keywords:
NPH, glargine, detemir,
children, adolescents
Received: 25 February, 2009
Accepted: 13 May, 2009
Corresponding Author:
Bumin Dündar, MD
Suleyman Demirel University,
Faculty of Medicine
Department of Pediatric
Endocrinology Cunur-32260-
Isparta, Turkey
Tel: +90-246-211 22 76
Fax: +90-246-211 22 09
E-mail:
bumindundar@gmail.com
ABSTRACT
Objective: The purpose of this study was to compare the efficacy and safety of insulin glargine
and detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus (DM).
Methods: Thirty four children and adolescents with type 1 DM (mean age 12.7 ± 3.4 years, dia-
betes duration 5.4 ± 3.0 years) were included in the study. All patients had been receiving inten-
sive insulin therapy with insulin aspart and NPH for at least 6 months before  switching from NPH
to insulin glargine (Group 1, n=19) or detemir (Group 2, n=15). The medical records obtained
within 6 months before and after treatment with insulin glargine and detemir were retrospec-
tively reviewed  and the data were compared in each group.
Results: The mean age and duration of DM were similar in two groups (p>0.05). In both groups,
switching from NPH to insulin glargine or detemir, resulted in a reduction in HbA1c (p<0.05, for
both). At the end of 6 months of treatment, no significant differences were observed between
the glargine- and detemir-treated groups with respect to HbA1c. Daily insulin requirements,
mean fasting blood glucose levels and frequency of severe hypoglycemia before and after treat-
ment with glargine and detemir were not significantly different (p>0.05, for both). Patients in
the detemir treated group had less increment in body mass index (BMI) SDS at the end of 6
months of therapy compared to NPH and glargine treated patients (p>0.05, for both).  No side
effects were noted throughout the study.
Conclusion: Both insulin glargine and detemir improved HbA1c at short-term and proved to be
safe and well tolerated in children and adolescents with type 1 DM. 
Conflict of interest: None declared
 
Creative
 
Commons Attiribution License which
 
distribution and reprodiction in any medium provided the original
This is an open-access article distributed under the terms of the
permits unrestricted 
work is properly cited
useINTRODUCTION
Diabetes Control and Complications Trial
(DCCT) has shown that intensive diabetes
management in adults and adolescents results
in better glycemic control and delays the
onset of vascular and neurological complica-
tions.
1 Intensive diabetes mellitus (DM) man-
agement consists of multiple daily injections
of both rapid and longer-acting insulin prepa-
rations which aim to mimic endogenous
insulin secretion pattern characterized by con-
tinuous basal insulin secretion and meal-relat-
ed peaks. In the past, human regular, NPH,
and ultralente insulins have all been used as
part of this regimen.
2 Recently however,
recombinant DNA technology has been used
to design new insulin molecules that over-
come the limitations of regular and NPH
insulin. Combinations of both rapid-acting
insulin analogues like insulin aspart and lispro
and long acting insulin analogues (LAIA) such
as insulin glargine and detemir have been
incorporated into treatment regimens.
3,4
Insulin glargine is a relatively new, long-
acting insulin analogue with a COOH-termi-
nal elongation of the B-chain by two
arginines and a replacement in the A-chain
of asparagine by glycine in position A21
(21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human
insulin). These modifications result in a shift
of the isoelectric point (from a pH of 5.4 to
6.7), making the new molecule less soluble
at physiological pH compared to the native
insulin molecule; consequently, insulin
glargine has a prolonged duration of action
that lasts approximately 24 hours, with no
pronounced peak in activity.
5 Another LAIA
is insulin detemir which is an acylated deriv-
ative of human insulin [Lys B29 (Nε -tetrade-
canoyl) des (B30) human insulin]. It has
more reproducible absorption and a pro-
longed action profile.
6
In recent years, due to their benefits
compared to NPH as basal insulin in the
treatment of type 1 DM, these LAIA have
been widely used in pediatric cases.
However, there are few studies available in
literature comparing the safety and efficacy
of these insulins in children and adolescents
with type 1 DM.
The aim of this study was to compare the
efficacy and safety of insulin glargine and
insulin detemir with NPH and with each
other in children with type 1 DM who have
been receiving intensive insulin therapy. 
METHODS
A total of 34 children and adolescents (19
female and 15 male) diagnosed with Type 1
DM who had regular controls at least for 1
year at our Pediatric Endocrinology
Department were included in the study. The
mean age of the patients and the mean dura-
tion of disease were 12.7 ± 3.4 and 5.4 ± 3.0
years, respectively. Previously, all patients had
been using intensive insulin therapy with 3
doses of insulin aspart and one dose of NPH
for at least 6 months. At onset of study, NPH
treatment was switched to insulin glargine
(Group 1, n=19) or detemir (Group 2, n=15)
once daily without any change in the rapid
acting insulin therapy.  Insulin glargine and
detemir treatments were started with a dose
that was 40-45% of total daily insulin doses.
Insulin to carbohydrate ratio for meals was not
used during the study period.  Characteristics
of the patients in Group 1 and Group 2 are
shown in Table 1. Four patients in group 1
(21%) and 3 patients in group 2 (20%) were
prepubertal. At the onset of treatment with the
new insulins, patients were informed about
the principles of action for insulin glargine and
insulin detemir. All patients had received the
same education regarding diabetes at the
onset of their disease.
The characteristics of Group 1 and
Group 2 are shown in Table 1. The mean
age and duration of DM were not significant-
ly different between the two groups
(p>0.05). All patients were evaluated every
three months. At each visit, a comprehensive
physical examination was done and patient
data including insulin doses, fasting glucose
levels, HbA1c values, frequency of severe
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measurements were recorded. Data pertain-
ing to the 6 month periods before and after
treatment with insulin glargine and detemir
were evaluated in the two groups.
HbA1c values were measured at baseline
and every 3 months, using the HPLC method
(normal value 5.1 ± 0.31%).
Severe hypoglycemia was defined as an
event with symptoms consistent with hypo-
glycemia in which the patient required assis-
tance from another person. The number of
attacks of severe hypoglycemia and noctur-
nal hypoglycemia during 6 months of treat-
ment with NPH and LAIA were recorded.
Fasting glucose values were recorded from
patient’s glucometer. All patients were
requested to check blood glucose at least 4
times per day and the mean value was cal-
culated. Weight and height measurements of
the patients were obtained using standard
devices. Body mass index (BMI) was deter-
mined using the formula: BMI= weight (kg)
/ height2 (m2) and BMI SDS was calculated
according to normal data obtained from sex
and age matched subjects.
7 Patients were
asked and examined for side effects and all
adverse events were noted at clinic visits.
This study has been conducted in accor-
dance with the guidelines in the Declaration
of Helsinki and has been formally approved
by local institutional ethical committee. 
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Table 1: Characteristics of the patients in Group 1 and Group 2 at onset of study*
Group 1 (n=19) Group 2 (n=15) Total (n=34)
Age (year) 13.0 ± 6.3 12.4 ± 3.2 12.7 ± 3.4 
Male/female (n) 10/9 7/3 17/12
BMI SDS -0.3 ±0.5 0.06 ±0.45 -0.17 ±0.48
Diabetes duration (years) 6.3 ± 2.8 4.2 ± 2.8 5.4 ± 3.0
*P>0.05 for comparison between Group 1 and Group 2 for all parameters
Table 2: Daily insulin requirements, mean fasting blood glucose levels and number of severe hypoglycemic attacks
in Group 1 on NPH and on insulin glargine
On NPH (n=19) On Glargine (n=19) p
BIR (U/kg) 0.63 ± 0.11 0.56 ± 0.12 >0.05
BBIR (U/kg) 0.97 ± 0.15 0.93 ± 0.18 >0.05
FBG (mg/dL) 216 ± 73.4 234 ± 69.1 >0.05
NNHA 0.26± 0.18 0.3± 0.21 >0.05
NDHA 5.9± 0.86 3.7± 0.18 >0.05
BIR: Bolus insulin requirement; BBIR: Basal and bolus insulin requirement; FBG: Fasting blood glucose; NNHA: Number of nocturnal hypoglycemic attacks;
NDHA: Number of day-time hypoglycemic attacks
Table 3: Daily insulin requirements, mean fasting blood glucose levels and number of severe hypoglycemic attacks
in Group 2 on NPH and on insulin detemir
On NPH (n=15) On Detemir (n=15) p
BIR (U/kg) 0.58± 0.12 0.48 ± 0.14 >0.05
BBIR (U/kg) 0.9± 0.15 0.81 ± 0.17 >0.05
FBG (mg/dL) 162 ± 35.6 134 ± 28.7 >0.05
NNHA 0.1± 0.07 0.1± 0.1 >0.05
NDHA 4.9± 0.93 3.1± 0.28 >0.05
BIR: Bolus insulin requirement; BBIR: Basal and bolus insulin requirement; FBG: Fasting blood glucose ; NNHA: Number of nocturnal hypoglycemic attacks;
NDHA: Number of day-time hypoglycemic attacksStatistical Analysis
SPSS 15 software package was used for
statistical analysis. Data were expressed as
mean ± standard error of the mean (SEM).
Statistical comparisons were performed
using non-parametric Mann-Whitney U,
Wilcoxon and Chi-square tests. Statistical sig-
nificance was defined as p<0.05.
RESULTS
The mean daily insulin requirements, the
mean fasting glucose levels and the frequen-
cy of severe hypoglycemic attacks observed
in Group 1 and Group 2 during 6 months of
therapy with NPH and LAIA are shown in
Table 2 and 3. Daily bolus and total insulin
doses during NPH treatment were similar to
the doses used during insulin glargine and
detemir treatments (p>0.05, for both). There
was also no difference in insulin doses
between patients treated with insulin
glargine and detemir during the study peri-
od (p>0.05).  The mean fasting blood glu-
cose levels did not change significantly dur-
ing NPH and LAIA treatment periods
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Figure 1: Mean HbA1c values on NPH and on glargine
treatment (9.21 ± 1.71 and 8.47 ± 1.04, p<0.05)
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Figure 3: Increase in BMI SDS on NPH and on glargine
treatment  (0.38 ± 0.25 and 0.40± 0.25, p>0.05)
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Figure 4: Increase in BMI SDS on NPH and on detemir
treatment  (0.43 ± 0.14 and 0.27 ± 0.15, p<0.05)
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Figure 2: Mean HbA1c values on NPH and on detemir
treatment  (9.26 ± 1.31 and 8.97 ± 1.4, p<0.05)(p>0.05, for both). The mean number of
severe hypoglycemic attacks during 6
months of treatment with NPH and LAIA
were not significantly different (p>0.05). The
number of nocturnal hypoglycemic events
were found to be reduced after treatment
with LAIA therapy, but the difference was
not significant (p>0.05).  (Before treatment
with LAIA: 5 (26%) episodes in two patients
in Group 1 and 3 (15%) episodes in two
patients in Group 2; after treatment with
LAIA: 2 (13%) episodes in 2 patients in
Group 1 and 1 (6%) episode in one patient
in Group 2).  
In both groups, the mean HbA1c values
decreased significantly from baseline after
initiating LAIA therapy (p<0.05, for both)
(Figure 1 and 2). However, no significant
difference was found between glargine and
detemir treated patients (p>0.05).   
The increase in BMI SDS in detemir-treat-
ed group during 6 months was significantly
lower than the increase noted in NPH and
glargine-treated groups (p<0.05) (Figure 3
and 4). Pre- and post-treatment increase in
BMI SDS in the glargine group was similar
(p>0.05). No side effects were observed dur-
ing treatment with glargine and detemir
insulin and both insulins were well tolerated.  
DISCUSSION
In this study, HbA1c values were found
to be significantly reduced in children with
type 1 DM using intensive insulin therapy
after their basal insulin was switched from
NPH to insulin glargine or detemir, without
any significant changes in daily insulin
requirements and fasting glucose levels. This
result seems to be consistent with  most of
the previous studies investigating the effect
of insulin glargine and detemir in adults and
children with type 1 DM in which improve-
ments in HbA1c values were shown with or
without any change in daily insulin require-
ments and fasting glucose levels.
8-11 On the
other hand, some studies did not report any
significant difference in HbA1c levels
between NPH and LAIA treatments; this is
probably due to discrepancies in sample
size, treatment regimens and patient charac-
teristics between these studies.
12,13 Although
the sample size of our study is small, our
results indicate that both insulin glargine and
detemir, administered as part of intensive
insulin therapy, have a more predictable glu-
cose-lowering effect than NPH treatment.
We think that this effect is probably associ-
ated with longer duration of action of these
insulins which enables them to mimic phys-
iological patterns more closely.
The frequency of attacks of severe hypo-
glycemia and the ratio of nocturnal hypo-
glycemic events were higher during NPH
treatment in the two groups compared with
respective values on LAIA therapy, but these
differences were not significant. However, it
is well known that LAIA shows a flat profile
of plasma insulin levels and no pronounced
peak of activity, both of which are character-
istics associated with a lower relative risk of
hypoglycemia, especially at night.
10-15
It has been demonstrated that glargine
and detemir have different pharmacokinetic
and pharmacodynamic properties.
14-16
However; there are few studies in children
and adolescents with type 1 DM comparing
the effects of these insulins. Kabadi
17 et al
showed worsening in HBA1c levels in
patients switching from insulin glargine to
insulin detemir twice a day.  In a study on
adult patients, Meneghini at al
18 reported that
HbA1c was significantly reduced from base-
line after starting  insulin detemir in patients
with type 2 DM who have previously
received NPH and glargine insulin. Monami
et al
19 on the other hand showed no signifi-
cant differences in a similar group of
patients. Although insulin requirements, fast-
ing glucose levels and HbA1c values during
treatment were similar in glargine and
detemir treated groups during the study
period in the present study, there is a need
for randomized, double-blind and controlled
studies to compare the effects of these
insulins in children with type 1 DM.
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detemir treated group was found to be
lower than the increase in patients treated
with NPH and glargine in this study. In pre-
vious studies, a weight advantage which
could not be explained by BMI-related dif-
ferences has also been reported with
insulin detemir compared to NPH
insulin.
13,20,21 A number of hypotheses have
been suggested to explain this observa-
tion.
22,23 The first, concerns the risk reduc-
tion for hypoglycemia typically observed
with insulin detemir and it has been sug-
gested that reduced nocturnal hypo-
glycemia may reduce the need for addition-
al precautionary calorie intake by the
patient.
24 Another potential explanation for
the weight-sparing property of insulin
detemir is that it might exert a greater effect
on endogenous hepatic glucose production
relative to peripheral glucose uptake, com-
pared to subcutaneously injected human
insulin.
25 This would imply that insulin
detemir could exert a relatively lower inhi-
bitiory effect on peripheral lipolysis for a
given total glucose-lowering effect. 
Injection site reactions have been report-
ed, particularly during insulin detemir
administration. However, no side effects
were observed in our patients. Both insulins
were well tolerated during the study period.
Nevertheless, long-term adverse effects of
insulin glargine and detemir in children are
still unknown.
In conclusion, our results indicate that
using insulin glargine or detemir instead of
NPH insulin in the treatment of children and
adolescents with type 1 DM receiving inten-
sive insulin management, improves metabol-
ic control with similar efficacy and without
increasing the number of hypoglycemic
events. Insulin detemir seems to have the
additional advantage of producing less
weight gain. Further carefully designed,
long-term, prospective studies are needed to
evaluate the overall benefits and clinical effi-
cacy of LAIA therapy in children and adoles-
cents with type 1 DM.
REFERENCES
1. Diabetes Control and Complications Trial
Research Group. The effect of intensive tre-
atment of diabetes on the development and
progression of long-term complications in
insulin-dependent diabetes mellitus. N Engl
J Med 1993;329:977-986. 
2. Hirsch IB. Intensive treatment of type 1 di-
abetes. Med Clin North Am 1998;82:689-
719.
3. Iafusco D. Insulin therapy regimens in paedi-
atric age. Acta Biomed 2005;76 Suppl 3:39-
43.
4. Sheldon B, Russell-Jones D, Wright J. Insulin
analogues: an example of applied medical
science. Diabetes Obes Metab 2009;11:5-
19.
5. Thisted H, Johnsen SP, Rungby J. An update
on the long-acting insulin analogue glargi-
ne. Basic Clin Pharmacol Toxicol 2006;99:1-
11.
6. Kurtzhals P, Havelund S, Jonassen I, Kiehr B,
Ribel U, Markussen J. Albumin binding and
time action of acylated insulins in various
species. J Pharm Sci 1996;85:304-308.
7. Ozturk A, Mazicioglu MM, Hatipoglu N, Bu-
dak N, Keskin G, Yazlak Z, Balci N, Yildiz H,
Yildiz K, Ustunbas HB, Kurtoglu S. Referen-
ce body mass index curves for Turkish chil-
dren 6 to 18 years of age. J Pediatr Endocri-
nol Metab 2008;21:827-836.
8. Chase HP, Arslanian S, White NH, Tamborla-
ne WV. Insulin glargine versus intermediate-
acting insulin as the basal component of
multiple daily injection regimens for adoles-
cents with type 1 diabetes mellitus. J Pediatr
2008;153:547-553. 
9. Colino E, López-Capapé M, Golmayo L,
Ålvarez MA, Alonso M, Barrio R. Therapy
with insulin glargine (Lantus®) in toddlers,
children and adolescents with type 1 diabe-
tes. Diabetes Res Clin Pract 2005;70:1-7.
10. Braun D, Konrad D, Lang-Muritano M,
Schoenle E. Improved glycemic control and
lower frequency of severe hypoglycemia
with insulin detemir; long-term experience
in 105 children and adolescents with type 1
diabetes. Pediatr Diabetes 2008;9:382-387.
11. Robertson KJ, Schoenle E, Gucev Z, Mord-
horst L, Gall MA, Ludvigsson J. Insulin dete-
mir compared with NPH insulin in children
Efficacy and Safety of Insulin Glargine and Insulin Detemir
© 2009 Journal of Turkish Pediatric Endocrinology and Diabetes Society 186and adolescents with Type 1 diabetes. Dia-
bet Med 2007;24:27-34.
12. Päivärinta M, Tapanainen P, Veijola R. Basal
insulin switch from NPH to glargine in chil-
dren and adolescents with type 1 diabetes.
Pediatr Diabetes 2008;9:83-90.
13. Fajardo Montañana C, Hernández Herrero
C, Rivas Fernández M. Less weight gain and
hypoglycaemia with once-daily insulin dete-
mir than NPH insulin in intensification of in-
sulin therapy in overweight Type 2 diabetes
patients: the PREDICTIVE BMI clinical trial.
Diabet Med 2008;25:916-923.
14. Porcellati F, Rossetti P, Busciantella NR, Mar-
zotti S, Lucidi P, Luzio S, Owens DR, Bolli
GB, Fanelli CG. Comparison of pharmacoki-
netics and dynamics of the long-acting insu-
lin analogs glargine and detemir at steady
state in type 1 diabetes: a double-blind, ran-
domized, crossover study. Diabetes Care
2007;30:2447-2452. Erratum in: Diabetes
Care. 2008;31:188.
15. Danne T, Datz N, Endahl L, Haahr H, Nesto-
ris C, Westergaard L, Fjording MS, Kordo-
nouri O. Insulin detemir is characterized by a
more reproducible pharmacokinetic profile
than insulin glargine in children and adoles-
cents with type 1 diabetes: results from a
randomized, double-blind, controlled trial.
Pediatr Diabetes 2008;9:554-560. 
16. Danne T, Lüpke K, Walte K, Von Schuetz W,
Gall MA. Insulin detemir is characterized by
a consistent pharmacokinetic profile across
age-groups in children, adolescents, and
adults with type 1 diabetes. Diabetes Care
2003;26:3087-3092.
17. Kabadi UM. Deleterious outcomes after ab-
rupt transition from insulin glargine to insu-
lin detemir in patients with type 1 diabetes
mellitus.  Clin Drug Investig 2008;28:697-
701.
18. Meneghini LF, Rosenberg KH, Koenen C,
Merilainen MJ, Lüddeke HJ. Insulin detemir
improves glycaemic control with less
hypoglycaemia and no weight gain in pati-
ents with type 2 diabetes who were insulin
naive or treated with NPH or insulin glargi-
ne: clinical practice experience from a Ger-
man subgroup of the PREDICTIVE study. Di-
abetes Obes Metab 2007;9:418-427.
19. Monami M, Marchionni N, Mannucci E.
Long-acting insulin analogues versus NPH
human insulin in type 2 diabetes: a meta-
analysis. Diabetes Res Clin Pract 2008;81:
184-189. 
20. Davies MJ, Derezinski T, Pedersen CB, Clau-
son P. Reduced weight gain with insulin de-
temir compared to NPH insulin is not explai-
ned by a reduction in hypoglycemia. Diabe-
tes Technol Ther 2008;10:273-277.
21. Bartley PC, Bogoev M, Larsen J, Philotheou
A. Long-term efficacy and safety of insulin
detemir compared to Neutral Protamine Ha-
gedorn insulin in patients with Type 1 diabe-
tes using a treat-to-target basal-bolus regi-
men with insulin aspart at meals: a 2-year,
randomized, controlled trial. Diabet Med
2008;25:442-449. 
22. Fritsche A, Haring H. At last, a weight neut-
ral insulin? Int J Obes 2004;28 Suppl. 2:S41-
S46.
23. Home P, Kurtzhals P. Insulin detemir: from
concept to clinical experience. Expert Opin
Pharmacother 2006;7:325-343.
24. Kølendorf K, Ross GP, Pavlic-Renar I, Perriel-
lo G, Philotheou A, Jendle J, Gall MA, Heller
SR. Insulin detemir lowers the risk of hypogl-
ycaemia and provides more consistent plas-
ma glucose levels compared with NPH insu-
lin in type 1 diabetes. Diabet Med 2006;23:
729-735.
25. Hordern SV, Wright JE, Umpleby AM, Sho-
jaee-Moradie F, Amiss J, Russell-Jones DL.
Comparison of the effects on glucose and li-
pid metabolism of equipotent doses of insu-
lin detemir and NPH insulin with a 16-h
euglycaemic clamp. Diabetologia 2005;48:
420-426.
Dündar B. N., et al
J Clin Res Ped Endo 2009;1(4):181–187 187